| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 8,544 | 17,470 | 10,135 | 10,784 |
| Short-term investments | 37,512 | 40,834 | 50,456 | 60,173 |
| Accounts receivable and unbilled receivable | 191 | 182 | 254 | 526 |
| Prepaid expenses and other current assets | 1,095 | 1,642 | 956 | 2,213 |
| Total current assets | 47,342 | 60,128 | 61,801 | 73,696 |
| Property and equipment, gross | 5,045 | NaN | NaN | NaN |
| Lessaccumulated depreciation and amortization | 4,554 | NaN | NaN | NaN |
| Property and equipment, net | 491 | 578 | 666 | 743 |
| Operating lease right-of-use assets | 495 | 629 | 764 | 899 |
| Other assets | 844 | 549 | 549 | 401 |
| Total assets | 49,172 | 61,884 | 63,780 | 75,739 |
| Accounts payable | 5,480 | 8,087 | 2,441 | 6,010 |
| Accrued liabilities | 8,337 | 7,577 | 11,539 | 9,938 |
| Operating lease liabilities | 646 | 730 | 726 | 721 |
| Total current liabilities | 14,463 | 16,394 | 14,706 | 16,669 |
| Operating lease liabilities, net of current portion | 0 | 102 | 284 | 464 |
| Total liabilities | 14,463 | 16,496 | 14,990 | 17,133 |
| Common stock, 0.0001 par value, 150,000 shares authorized 68,370 and 68,305 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 7 | 7 | 7 | 7 |
| Additional paid-in capital | 477,126 | 475,361 | 471,547 | 470,138 |
| Accumulated other comprehensive gain (loss) | -49 | 50 | 50 | 17 |
| Accumulated deficit | -442,375 | -430,030 | -422,814 | -411,556 |
| Total stockholders equity | 34,709 | 45,388 | 48,790 | 58,606 |
| Total liabilities and stockholders equity | 49,172 | 61,884 | 63,780 | 75,739 |
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)